CHAPEL HILL, N.C., Aug. 12 /PRNewswire/ -- Cempra Pharmaceuticals today announced the appointment of John H. Johnson, Chief Executive Officer of ImClone Systems, a wholly-owned subsidiary of Eli Lilly and Company, to the company's Board of Directors. Mr. Johnson brings more than 25 years of biopharmaceutical executive and operational management experience, including leadership of successful anti-infective businesses and numerous flagship pharmaceutical products, to his role as an independent member of the Board.
"I've been closely tied to the antibacterial and public health product markets throughout my career in the biopharmaceutical industry, and Cempra's clinical-stage anti-infective programs address an absolutely critical market need for safe, potent antibiotics," said Mr. Johnson. "Cempra is at a turning point in the company's development of its two lead compounds, as both are poised to advance into later stage clinical trials. I look forward to working with Cempra's other Board members and management to enable the success of these much-needed drugs."
Cempra's lead macrolide, CEM-101, will soon enter a Phase 2 clinical trial for moderate to moderately severe community-acquired bacterial pneumonia. Cempra has also initiated an adaptive design Phase 2/3 trial in acute bacterial skin structure infections for CEM-102, an antibiotic with an established record of treating staphylococcal infections, including methicillin-resistant Staphylococcus aureus (MRSA). Cempra recently completed a $46 million Series C financing that will fund the further development of these compounds.
"John's respected reputation, deep knowledge of the antibacterial market and strong business acumen makes him an extremely well-positioned, highly-valued addition to our Board of Directors," said Prabhavathi Fernandes, President and CEO, Cempra Pharmaceuticals. "Following a ve
|SOURCE Cempra Pharmaceuticals|
Copyright©2009 PR Newswire.
All rights reserved